Success Metrics

Clinical Success Rate
66.7%

Based on 10 completed trials

Completion Rate
67%(10/15)
Active Trials
2(11%)
Results Posted
40%(4 trials)
Terminated
5(26%)

Phase Distribution

Ph phase_3
1
5%
Ph phase_2
8
42%
Ph not_applicable
2
11%
Ph phase_1
8
42%

Phase Distribution

8

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
8(42.1%)
Phase 2Efficacy & side effects
8(42.1%)
Phase 3Large-scale testing
1(5.3%)
N/ANon-phased studies
2(10.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

10 of 15 finished

Non-Completion Rate

33.3%

5 ended early

Currently Active

2

trials recruiting

Total Trials

19

all time

Status Distribution
Active(2)
Completed(10)
Terminated(5)
Other(2)

Detailed Status

Completed10
Terminated5
unknown2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (42.1%)
Phase 28 (42.1%)
Phase 31 (5.3%)
N/A2 (10.5%)

Trials by Status

completed1053%
terminated526%
unknown211%
active_not_recruiting15%
recruiting15%

Recent Activity

2 active trials
Showing 5 of 19
completedphase_1

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

NCT03123978
recruitingphase_1

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

NCT05188170
completedphase_2

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

NCT04870333
completedphase_2

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
completedphase_1

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

NCT04705415
View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials
NCT03123978Phase 1

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Completed
NCT05188170Phase 1

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Recruiting
NCT04870333Phase 2

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Completed
NCT04603924Phase 2

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Completed
NCT04705415Phase 1

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Completed
NCT02807805Phase 2

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Active Not Recruiting
NCT04858425Phase 2

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Terminated
NCT03521232Phase 1

A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

Terminated
NCT04317430Phase 3

Niclosamide Role in Diabetic Nephropathy

Completed
NCT04399356Phase 2

Niclosamide for Mild to Moderate COVID-19

Completed
NCT04932915Phase 2

Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

Terminated
NCT04644705Phase 1

Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat

Completed
NCT04296851Phase 2

Niclosamide for Familial Adenomatous Polyposis

Unknown
NCT02687009Phase 1

A Study of Niclosamide in Patients With Resectable Colon Cancer

Terminated
NCT03160001Phase 1

Niclosamide With Etanercept in Rheumatoid Arthritis

Completed
NCT02519582Phase 2

Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy

Unknown
NCT02532114Phase 1

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

Completed
NCT01296958Not Applicable

Targeted Screening for Taenia Solium Tapeworms

Completed
NCT00138359Not Applicable

Mass Treatment T Solium Community Study

Terminated

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19